Kurcz powiek – od rozpoznania do właściwego leczenia

##plugins.themes.bootstrap3.article.main##

Michał Schinwelski

Abstrakt

Wprowadzenie: Kurcz powiek (blepharospasm) jest zaburzeniem ruchowym charakteryzującym się mimowolnym skurczem mięśni zamykających oczy. Ta druga co do częstości dystonia ogniskowa występująca w wieku dorosłym wciąż budzi wiele wątpliwości zarówno wśród okulistów, jak i neurologów.


Cel: Przedstawienie aktualnej wiedzy na temat kurczu powiek na tle rysu historycznego choroby.


Metody: Przegląd literatury dotyczącej rozpoznania, patofizjologii i leczenia kurczu powiek.


Wyniki: Różne typy skurczów mięśni zamykających oczy, rozprzestrzenianie się dystonii na dolną część twarzy i szyję, współwystępowanie apraksji otwierania powiek, częstego mrugania, trików czuciowych oraz zaburzeń psychiatrycznych definiują kurcz powiek jako heterogenną jednostkę chorobową. Aktualne badania genetyczne, elektrofizjologiczne i neuroobrazowe przynoszą wiedzę na temat złożonych i wieloogniskowych generatorów ruchów mimowolnych definiujących kurcz powiek wraz z innymi dystoniami ogniskowymi jako „chorobę węzła komunikacyjnego”, w której toksyna botulinowa działająca na końcu wszystkich ścieżek patologicznych jest leczeniem z wyboru.


Wnioski: Historia kurczu powiek jako choroby neurologicznej dotykającej narządu wzroku pokazuje, że najważniejsze odkrycia dotyczące rozpoznania, patofizjologii oraz leczenia tej choroby miały miejsce zarówno dzięki okulistom, jak i neurologom. Dlatego przyszłość opisywanej choroby również będzie zależała od tej współpracy.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Schinwelski M. Kurcz powiek – od rozpoznania do właściwego leczenia. Ophthatherapy [Internet]. 31 marzec 2019 [cytowane 3 lipiec 2024];6(1):43-0. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/509
Dział
Artykuły

Bibliografia

1. Garcia-Ruiz PJ, Slawek J, Sitek EJ et al. Art and Dystonia. J Neurol Sci. 2015; 356(1-2): 49-54.
2. Mackenzie W. Case of intense and long-continued photophobia and blepharospasm relieved by the inhalation of chloroform. Med Chi Trans. 1857; 40: 175-8.
3. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome). A variant of adult onset torsion dystonia? J Neurol Neurosurg Psychiatry. 1976; 39: 1204-9.
4. Steeves TD, Day L, Dykeman J et al. The prevalence of primary dystonia: a systematic review and meta analysis. Mov Disord. 2012; 27: 1789-96.
5. Martino D, Livrea P, Giorelli M et al. Menopause and menarche in patients with primary blepharospasm: an exploratory case-control study. Eur Neurol. 2002; 47: 161-4.
6. Conte A, Defazio G, Ferrazzano G et al. Is increased blinking a form of blepharospasm? Neurology. 2013; 80: 2236-41.
7. Lamberti P, De Mari M, Zenzola A et al. Frequency of apraxia of eyelid opening in the general population andbin patients with extrapyramidal disorders. Neurol Sci. 2002; 23(2): S81-2.
8. Defazio G, Livrea P, Lamberti P et al. Isolated So-Called Apraxia of Eyelid Opening: Report of 10 Cases and a Review of the Literature. Eur Neurol. 1998; 39: 204-10.
9. Krack P, Marion MH. “Apraxia of lid opening” a focal eyelid dystonia: clinical study of 32 patients. Mov Disord. 1994; 9: 610-5.
10. Umemura A, Toyoda T, Yamamoto K et al. Apraxia of eyelid opening after subthalamic deep brain stimulation may be caused by reduction of levodopa. Parkinsonism Relat Disord. 2008; 14: 655-7.
11. Weiss D, Wächter T, Breit S et al. Involuntary eyelid closure after STN-DBS: evidence for different pathophysiological entities. J Neurol Neurosurg Psychiatry. 2010; 81: 1002-7.
12. Abbruzzese G, Berardelli A, Girlanda P et al. Long-term assessment of the risk of spread in primary late-onset focal dystonia. J Neurol Neurosurg Psychiatry. 2008; 79: 392-6.
13. Berardelli A, Abbruzzese G, Chen R et al. Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders. Brain Stimul. 2008; 1: 183-91.
14. Defazio G, Matarin M, Peckham EL et al. The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm. Mov Disord. 2009; 24: 613-6.
15. Adams WH, Digre KB, Patel BC et al. The evaluation of light sensitivity in benign essential blepharospasm. Am J Ophthalmol. 2006; 142: 82-7.
16. Blackburn MK, Lamb RD, Digre KB et al. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. Ophthalmology. 2009; 116: 997-1001.
17. Grandas F, Elston J, Quinn N et al. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988; 51(6): 767-72.
18. Martino D, Liuzzi D, Macerollo A et al. The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia. Mov Disord. 2010; 25: 407-12.
19. Schramm A, Reiners K, Naumann M. Complex mechanisms of sensory tricks in cervical dystonia. Mov Disord. 2004; 19: 452-8.
20. Brissaud E. Vingt-quatrième leçon. Tics et spasmes cloniques de la face. In: Meige H (ed). Leçons sur les maladies nerveuses: La Salpêtrière 1893–1894. Paris: Masson 1895: 502-20.
21. Fabbrini G, Berardelli I, Moretti G et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010; 25: 459-65.
22. Broocks A, Thiel A, Angerstein D, Dressler D. Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm. Am J Psychiatry. 1998; 155: 555-7.
23. Defazio G, Hallett M, Jinnah HA, Berardelli A. Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology. 2013; 81: 236-40.
24. Albanese A, Sorbo FD, Comella C et al. Dystonia rating scales: critique and recommendations. Mov Disord. 2013; 28: 874-83.
25. Defazio G, Hallett M, Jinnah HA et al. Development and validation of a clinical scale for rating the severity of blepharospasm. Mov Disord. 2015; 30: 525-30.
26. Defazio G, Martino D, Aniello MS et al. A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006; 77: 252-4.
27. Fuchs T, Saunders-Pullman R, Masuho I et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet. 2013; 45: 88-92.
28. Charlesworth G, Plagnol V, Holmström KM et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet. 2012; 91: 1041-50.
29. Hersheson J, Mencacci NE, Davis M et al. Mutations in the autoregulatory domain of b-tubulin 4a cause hereditary dystonia. Ann Neurol. 2013; 73: 546-53.
30. Xiao J, Uitti RJ, Zhao Y et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol. 2012; 71: 458-69.
31. Defazio G, Abbruzzese G, Aniello MS et al. Eye symptoms in relatives of patients with primary adult-onset dystonia. Mov Disord. 2012; 27: 305-57.
32. Defazio G, Martino D, Abbruzzese G et al. Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control study. J Neurol Neurosurg Psychiatry. 2007; 78: 877-9.
33. Khooshnoodi MA, Factor SA, Jinnah HA. Secondary blepharospasm associated with structural lesions of the brain. J Neurol Sci. 2013; 331: 98-101.
34. Rana AQ, Kabir A, Dogu O et al. Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor. Eur Neurol. 2012; 68: 318-21.
35. Zadori D, Veres G, Szalardy L et al. Druginduced movement disorders. Expert Opin Drug Saf. 2015; 14: 877-90.
36. Valls-Sole J, Montero J. Movement disorders in patients with peripheral facial palsy. Mov Disord. 2003; 18: 1424-35.
37. Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain. 1985; 108: 593-608.
38. Conte A, Defazio G, Ferrazzano G et al. Is increased blinking a form of blepharospasm? Neurology. 2013; 80: 2236-41.
39. Quartarone A, Morgante F, Sant’angelo A et al. Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. J Neurol Neurosurg Psychiatry. 2008; 79: 985-90.
40. Feiwell RJ, Black KJ, McGee-Minnich LA et al. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm. Neurology. 1999; 52: 291-7.
41. Dresel C, Haslinger B, Castrop F et al. Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia. Brain. 2006; 129: 36-46.
42. Yang J, Luo C, Song W et al. Diffusion tensor imaging in blepharospasm and blepharospasm-oromandibular dystonia. J Neurol. 2014; 261: 1413-24.
43. Henderson JW. Essential blepharospasm. Trans Am Ophthalmol Soc. 1956; 54: 453-520.
44. Nutt JG, Hammerstad JP, deGarmo P, Carter J. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology. 1984; 34: 215-7.
45. Gurdjian ES, Williams HW. The surgical treatment of intractable blepharospasm. JAMA. 1928; 91: 2053-6.
46. Coleman CC. Surgical treatment of facial spasm. Ann Surg. 1937; 105: 638-57.
47. Greenwood J. The surgical treatment of hemifacial spasm. J Neurosurg. 1946; 3: 506-10.
48. Gillum WN, Anderson RL. Blepharospasm surgery: anatomic approach. Arch Ophthalmol. 1981; 99: 1056-62.
49. Anderson RL, Patel BC, Holds JB et al. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998; 14: 305-7.
50. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980; 87: 1044-9.
51. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985; 103: 347-50.
52. Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86: 1818-26.
53. Bilyk JR, Yen MT, Bradley EA et al. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018; 125(9): 1459-67.
54. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999; 354: 259-68.
55. Dressler D, Pan L, Adib Saberi F. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Transm (Vienna). 2018; 125(10): 1481-6.
56. Jost WH, Kohl A. Botulinum toxin: evidence based medicine criteria in blepharospasm and hemifacial spasm. J Neurol. 2001; 248(1): 21-4.
57. Albanese A, Bentivoglio AR, Colosimo C et al. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J Neurol Neurosurg Psychiatry. 1996; 60: 693-4.
58. Levy RL, Berman D, Parikh M, Miller NR. Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology. 2006; 113(9): 1665-8.
59. Ochudło S, Bryniarski P, Opala G. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord. 2007; 13(8): 505-8.
60. Calace P, Cortese G, Piscopo R et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol. 2003; 13(4): 331-6.
61. Dressler D, Karapantzou C, Rohrbach S et al. Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results. J Neural Transm (Vienna). 2017; 124(2): 253-7.
62. Reese R, Gruber D, Schoenecker T et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord. 2011; 26: 691-8.
63. Lorenzano D, Tansley S, Ezra DG. Sensory Trick Frames: A New Device for Blepharospasm Patients. J Mov Disord. 2019; 12(1): 22-6.
64. Macerollo A, Superbo M, Gigante AF et al. Diagnostic delay in adult-onset dystonia: data from an Italian movement disorder center. J Clin Neurosci. 2015; 22(3): 608-10.